My hands shook as I texted my husband. I felt unmoored in my body, as if I’d awoken in a different house than the one where I ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

The rash associated with shingles usually crusts over within seven to 10 days for people with a healthy immune system and ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

While red and itchy like other rashes, the shingles rash is otherwise very distinct. Vesicles (fluid-filled sacs) are ...

The FDA approved lebrikizumab (Ebglyss) for treating atopic dermatitis in adults and children ages 12 years and up, drugmaker ...

The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for ...

Ruxolitinib can cause cytopenia, the most prominent adverse event (AE). There are rates of anemia and thrombocytopenia in ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for ... on Thursday ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

The US food and Drug Administration has approved lebrikizumab for treatment of atopic dermatitis in adults and children ages ...